The growth peculiarities of human and mouse tumour explants and isolated tumour cells under the influence of immunomodulators different nature

Experimental Oncology

Volumn 18, Issue 2, 1996, Pages 244-250

  Berezhnaya, N M ^a   Kovalchouk, E V ^a   Denisevich, T V ^a   Osipova, E V ^a   Konovalenko, V F ^b   Tolstopyatov, B A ^b   Trembach, A M ^b   Protsik, V S ^b   Vorobjova, L I ^b   Pinchouk, V G ^a   Yakshibayeva, Yu R ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Ministry of Health of Ukraine   (Ukraine)

Author keywords

Immunomodulators; Spheroid formation; Tumour explants and cells

Indexed keywords

EID: 3643050950     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Dodet B. Cytokines in the clinics. Choose your weapon! Eur Cyt Network 1994; 5: 369-78.
2. Stein R, Dalgleish A. Immunomodulatory agents: the cytokines. Eur J Cancer 1994; 30A: 400-4.
3. Immune modulation and control of neoplasia by adjuvant therapy. Chirigos A, ed. New York: Raven Press, 1978. 502 pp.
4. Amery WK, Horig C. Effects of immunomodifiers on thymus lymphocytes. In: Fenichel RL, Chirigos MA, eds. Immune Modulation Agents and Their Mechanisms. New York: Marcel Dekker Inc, 1984: 383-408.
5. Low TLK, Loldstein AL. Natural products, extracts and low molecular weight components. Thymosin, peptidic moieties and related agents. In: Fenichel RL, Chirigos MA, eds. Immune Modulation Agents and Their Mechanisms. New York: Marcel Dekker Inc, 1984: 135-62.
6. α1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T-cell-mediated tumor regression and development of antitumor immunity. Comparative studies with IFN-γ-producing TS/A cells. Immunol 1994; 153: 4605-15.
7. Berezhnaya NM, Osipova EV, Kovalchuk EV et al. The evidence of possibility of interleukin-2 receptor expression on human solid tumors different histogenesis. Exp Oncol 1994; 16: 40-7.
8. Barton D, Blanchard D, Wells A et al. Expression of interleukin-2 receptor alpha (122-2Ra), mRNA and protein in advanced epithelial ovarian cancer. Anticancer Res 1994; 14 (3A): 761-72.
9. Jasmin C. Structure and function of the IL-2/IL-15 receptor present on human melanoma cells impact for IL-2 therapy. Tumor microenvironment progression therapy and prevention. In: Abstr Int Conf, Israel, 1995: 35.
10. Goodrich KH, Alvazez X, Holcombe R. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer 1993; 72: 225-30.
11. Abdalla EE, Blair GE, Jones RA et al. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Nat Cancer Inst 1995; 87: 489-96.
12. Moertel CL, Flemig TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 1990; 322: 352-8.
13. Hayasten C, Koval T. Radiosensitization of human tumor cells with levamisole. Cancer Res 1992; 52: 3228-31.
14. Grem JL, Allegra CG. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Nat Cancer Inst 1989; 81: 1413-7.
15. Grem JL. Levamisole as a therapeutic agent for colorectal carcinoma. Cancer Cells 1990; 2: 131-7.
16. Stevenson HC, Green G, Hamilton JM et al. Levamisole: known effects on the immune system, clinical results and future application to the treatment of cancer. J Clin Oncol 1991; 9: 2052-66.
17. Aulitzky W, Huber C, Peschel C. Cytokine therapy of neoplastic and inflammatory diseases. Int Arch Allergy Immunol 1993; 101: 221-6.
18. α-types of human and mouse interferon. Antiviral Res 1981; 1: 167-78.